Jonathan E. Dickinson

Executive Vice President & General Manager, Europe at Incyte Corp.

Jonathan E. Dickinson

Jonathan E. Dickinson

Executive Vice President & General Manager, Europe at Incyte Corp.

Overview
RelSci Relationships

319

Relationships
RelSci Relationships are individuals Jonathan E. Dickinson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman, President & Chief Executive Officer at Incyte Corp.

Relationship likelihood: Strong

President & Director at ARIAD Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Madrigal Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Medical Officer at Incyte Corp.

Relationship likelihood: Strong

Vice President, Finance & Chief Accounting Officer at Incyte Corp.

Relationship likelihood: Strong

Executive Vice President & General Manager, North America at Incyte Corp.

Relationship likelihood: Strong

Executive Vice President & Head of Discovery Chemistry at Incyte Corp.

Relationship likelihood: Strong

Head of Patient Advocacy at Incyte Corp.

Relationship likelihood: Strong

Senior Director-Investor Relations at Incyte Corp.

Relationship likelihood: Strong

Executive Vice President & Head of Global Technical Operations at Incyte Corp.

Relationship likelihood: Strong

Paths to Jonathan E. Dickinson
Potential Connections via
Relationship Science
You
Jonathan E. Dickinson
Executive Vice President & General Manager, Europe at Incyte Corp.
Education
M.B.A. Degree

Nottingham University Business School is an international, tri-campus business school with campuses in the UK, China and Malaysia, strong connections to the corporate world and highly rated influential research.Nottingham University Business School provide outstanding teaching programmes and support that enable our students to excel in a global environment.Nottingham University Business School influential research is ranked as 'internationally excellent', with world leading strengths in banking and finance, entrepreneurship, innovation and business sustainability.

B.Sc. Degree in Genetics

The University of Nottingham shares many of the characteristics of the world's great universities. However, they are distinct not only in their key strengths but in how their many strengths combine: they are financially secure, campus based and comprehensive; they are research-led and recruit top students and staff from around the world; they are committed to internationalising all their core activities so their students can have a valuable and enjoyable experience that prepares them well for the rest of their intellectual, professional and personal lives.

Career History
General Manager
2013 - Current

ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA.

Executive Vice President & General Manager, Europe
Current

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Product Manager & Business Director
Prior

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jonathan E. Dickinson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jonathan E. Dickinson's profile does not indicate a business or promotional relationship of any kind between RelSci and Jonathan E. Dickinson.